Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $74.5552W HIGH $191.05
Volume
1.50 M
Value Traded
256.98 M
Short % Float
9.06%
Days to Cover
6.7
+3.2%Week
+2.32%1 Month
+12.57%3 Month
+96.12%6 Month
-3.01%5 Year
+328.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
23.99 B
EPS (TTM)
-3.38
P/E Ratio
-
Ent. Value
24.44 B
Total Shares
134.21 M
Float Shares
128.76 M
Insiders
4.05%
Institutions
101.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
GH Catalyst Timeline
Dated clinical, regulatory and corporate events for Guardant Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Guardant Health, Inc.
249Total events
6Upcoming
72Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Reimbursement / PricingShieldApprovedPost-Market
Pennsylvania HB 1123 enacted aligning insurance coverage for CRC screening with no cost-sharing for Shield
colorectal cancer screeningsource ↗
◆Oral PresentationPresentation
Rapid Oral LBA73: ctDNA-guided treatment intensification in PACE-LUNG
EGFR-mutant non-small cell lung cancersource ↗
◆Oral PresentationlorlatinibPresentation
Rapid Oral 2636RO: resistance mechanisms and predictors of response to lorlatinib from CROWN
NSCLCsource ↗
◆Poster PresentationPresentation
Poster 8P: efficacy and predictive biomarkers of mTOR inhibition plus endocrine therapy after PI3K inhibitors
hormone receptor-positive metastatic breast cancersource ↗
◆Poster PresentationelacestrantPresentation
Poster 45P: real-world elacestrant outcomes in ESR1-mutant HR+/HER2- mBC
ESR1-mutant HR+/HER2- metastatic breast cancersource ↗
◆Oral PresentationencorafenibPresentation
Rapid Oral 787RO: ctDNA-guided re-treatment with encorafenib and cetuximab in BRICKET
BRAF V600E-mutant metastatic colorectal cancersource ↗
◆Oral PresentationbemarituzumabPresentation
Rapid Oral 283RO: bemarituzumab by FGFR2 amplification status in FORTITUDE
gastric and gastroesophageal junction cancersource ↗
◆Poster PresentationPresentation
Poster 4403P: serial Guardant360 liquid testing during anti-EGFR rechallenge in mCRC
metastatic colorectal cancersource ↗
◆Poster Presentationtrastuzumab deruxtecanPresentation
Poster 4279P: ctDNA molecular response analysis from DESTINY-Breast06
HR+, HER2-low metastatic breast cancersource ↗
▲Full ResultsShieldApprovedClinical Data
New modeling and real-world adherence data for Shield presented at ACG 2026 Annual Meeting
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
Guardant360 CDx receives CE-marking in Europe as CDx for ETCAMAH (camizestrant)
ER-positive, HER2-negative locally advanced or metastatic breast cancersource ↗
▲EU Approvalardant360ApprovedEx-US Regulatory
Guardant360 CDx receives CE-marking in Europe as CDx for ETCAMAH (camizestrant)
ER-positive, HER2-negative locally advanced or metastatic breast cancersource ↗
▲Full ResultsClinical Data
Full COSMOS-MEL01 results: 81% sensitivity, 100% specificity, 70.5-day median lead time
resected stage II–III melanomasource ↗
▲PublicationPresentation
COSMOS-MEL01 results published in Cancer Research Communications
resected stage II–III melanomasource ↗
▲RWE DataShieldApprovedClinical Data
Modeling study projects blood-based screening increases colonoscopies and averts more CRC deaths vs FIT and mt-sDNA
colorectal cancersource ↗
▲Poster PresentationShieldApprovedPresentation
Guardant Health and collaborators present new Shield CRC screening data at ACG 2026 Annual Meeting
colorectal cancersource ↗
▲Oral PresentationShieldApprovedPresentation
Guardant and collaborators presented Shield real-world adherence and modeling data at ACG 2026
colorectal cancer screeningsource ↗
●Poster PresentationPresentation
Poster P2.184: Impact of Common Resistance Mechanisms on Real-World Overall Survival for Patients Receiving Osimertinib
NSCLCsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approves Guardant360 CDx as companion diagnostic for ETCAMAH in advanced breast cancer
HR-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutationssource ↗
▲Product LaunchShieldApprovedPost-Market
UnitedHealth Group covers Shield blood test for colorectal cancer screening
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for Boehringer Ingelheim's HERNEXEOS
companion diagnostic for HERNEXEOSsource ↗
▲Other Regulator MilestoneShieldApprovedEx-US Regulatory
American Cancer Society recommends Shield blood test in updated CRC screening guidelines
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for VEPPANU (vepdegestrant)
ER+/HER2- advanced breast cancer with ESR1 mutationssource ↗
▲Partnership / LicenseCorporate
Multi-year strategic collaboration with Nuvalent to develop companion diagnostics
oncologysource ↗
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for HERNEXEOS
HER2 (ERBB2)-mutant advanced non-small cell lung cancersource ↗
▲FDA ApprovalShieldApprovedFDA Decision
FDA approval for higher-throughput, lower-COGS Shield workflow
colorectal cancer screeningsource ↗
▲Reimbursement / PricingShieldApprovedPost-Market
Shield coverage obtained from UnitedHealth Group
colorectal cancer screeningsource ↗
▲FDA Approvalardant360ApprovedFDA Decision
First Guardant360 CDx companion diagnostic approval in colorectal cancer
colorectal cancersource ↗
▲Product LaunchPost-Market
Expanded tissue-free Guardant Reveal to include late-stage therapy response monitoring
late-stage therapy response monitoringsource ↗
●FDA Filing AcceptedRegulatory Filing
Submitted Guardant Reveal chemotherapy monitoring data package to MolDx for Medicare reimbursement
chemotherapy monitoringsource ↗
▲Partnership / LicenseCorporate
Established strategic collaboration with Merck to develop companion diagnostics and commercialize new cancer therapies
▲Product LaunchShieldApprovedPost-Market
Shield CRC received coverage through TRICARE for active-duty service members and families
colorectal cancer screeningsource ↗
◆Oral PresentationPresentation
Guardant Health to participate in upcoming investor conferences
◆Quarterly UpdateCorporate
Planned Q4 and full year 2025 audited financial results earnings call
▲FDA Approvalardant360ApprovedFDA Decision
FDA approval of Guardant360 CDx as companion diagnostic for BRAFTOVI combination in BRAF V600E-mutant mCRC
BRAF V600E-mutant metastatic colorectal cancersource ↗
▲Partnership / LicenseCorporate
Multi-year strategic collaboration with Merck to develop companion diagnostics and commercialize new cancer therapies using Guardant Infinity Smart platform
oncologysource ↗
▲Partnership / LicenseCorporate
Announced collaboration with Nuvalent to develop companion diagnostics
▲FDA Approvalardant360ApprovedFDA Decision
FDA approved Guardant360 CDx as companion diagnostic for VEPPANU
ER+/HER2- ESR1 mutated advanced breast cancersource ↗
▲Partnership / LicenseShieldApprovedCorporate
Launched nationwide multi-year collaboration with Quest to expand Shield access
colorectal cancer screeningsource ↗
▲Product LaunchPost-Market
Launched Shield Multi-Cancer Detection in Asia through Manulife partnership
multi-cancer detectionsource ↗
Past FDA Catalysts and PDUFA Decisions
How GH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Guardant Health, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every GH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Shield blood test | colorectal cancer | 2023-05-09 | sensitivity: 83%; specificity: 90%; stage I III sensitivity: 73%; localized case sensitivity: 70%Read More | Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield blood test Shield blood test achieved overall 83% sensitivity and 90% specificity and demonstRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MIGNONE ROBERTODirector | Option | 264 10,538 held | $0.00 | 10/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 7.4 % (48 %) | 509.10 M | 3.39 M | 1.65% ( 55.07 K) |
GH Institutional Ownership Trends
GH Short Interest
Shares sold short, counted twice a month.
9.06%
Short % of Float
of tradable shares sold short
11.7M
Shares Sold Short
-2.1% vs prior count
6.7 High
Days to Cover
trading days of normal volume to buy every short share back
1.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GH ranks across every disease it competes in
Competitive Position is a premium feature
See how GH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGH News
GH▼ -3.9%today
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
Guardant Health praised Pennsylvania's new law (HB 1123) that provides no cost-sharing for colorectal cancer screenings, benefiting about 2 million eligible residents. The law aligns insurance coverage with updated guidelines from the American Cancer Society and National Comprehensive Cancer Center. The Shield blood test, now included in these guidelines, aims to improve early detection rates.
Read more →GHGuardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Guardant Health will present 25 abstracts at ESMO 2026 in Madrid. The data highlights liquid biopsy advances in lung, colorectal, and gastric cancers. Key studies assess ctDNA-guided treatment intensification and minimal residual disease surveillance. These findings aim to improve patient selection and risk stratification for oncology therapies.
Read more →GHTwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent
TwinStrand Biosciences announced that the U.S. Patent Trial and Appeal Board has upheld all claims of its core patent related to Duplex Sequencing technology. This decision follows a challenge from Guardant Health, which was rejected by the PTAB. The ruling reinforces TwinStrand's intellectual property position and supports the validity of its innovative technology.
Read more →GHGuardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health presented new data at the ACG 2026 Annual Meeting, demonstrating the effectiveness of its Shield blood test for colorectal cancer screening. The study highlighted a 99% adherence rate in medically underserved populations and showed that blood-based testing outperformed stool-based methods in averting colorectal cancer deaths. This reinforces the importance of blood tests in improving screening participation and outcomes.
Read more →GHGuardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health has announced that its Guardant360® CDx has received CE-marking approval in Europe. This diagnostic tool is designed to identify patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from AstraZeneca's ETCAMAH™ (camizestrant). This approval marks a significant step in precision oncology for breast cancer treatment.
Read more →GHGuardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
Guardant Health, a precision oncology company, will report its third quarter 2026 financial results on November 5, 2026. The announcement includes a conference call for investors, which will be webcasted live. This event highlights the company's commitment to transparency and engagement with stakeholders.
Read more →GHGuardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
Guardant Health has announced the publication of the COSMOS-MEL01 study results in Cancer Research Communications. This study is significant as it is the first prospective, multicenter evaluation of the Guardant Reveal™ blood test, which is designed for detecting molecular residual disease and monitoring recurrence in melanoma patients. The findings support the test's utility in clinical settings.
Read more →GHGuardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health's Shield blood test for colorectal cancer screening will be covered by EviCore starting January 1, 2027. This coverage expansion significantly increases access to the test for approximately 94 million eligible patients aged 45 and older. The Shield test is recognized as the leading blood test for CRC screening, demonstrating high adherence rates in real-world settings.
Read more →GHGuardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
Guardant Health, a precision oncology company, will present 20 abstracts at the 2026 World Conference on Lung Cancer. These presentations will focus on advancements in methylation-based tumor classification and liquid biopsy technology for lung cancer subtypes. The conference is organized by the International Association for the Study of Lung Cancer.
Read more →GHBusiness Insider Names Guardant Health One of America's Most Innovative Businesses
Guardant Health has been named one of America's Most Innovative Businesses by Business Insider, receiving a five-star rating. This recognition highlights the company's leadership in precision oncology, driven by substantial R&D investments and innovative products. Guardant's advancements, including the Guardant360 Liquid CDx and Shield tests, underscore its commitment to improving cancer detection and treatment.
Read more →GHGuardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
Guardant Health has received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH in advanced breast cancer. This marks a significant advancement in cancer management, allowing for proactive monitoring of ESR1 mutations. The approval is based on the SERENA-6 trial, which demonstrated a 56% reduction in disease progression risk. This new approach aims to enhance patient outcomes through early intervention.
Read more →GHGuardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Guardant Health, Inc. announced that its Shield blood test for colorectal cancer screening will be covered by Carelon Healthcare Services starting November 15. Carelon is a significant specialty benefits manager in the U.S., enhancing the test's accessibility across more than 14 states. This coverage marks an important step for colorectal cancer detection.
Read more →GHGuardant Health to Appeal Federal District Court Judgment
Guardant Health, Inc. announced its intention to appeal a federal court judgment regarding intellectual property claims from TwinStrand Biosciences and the University of Washington. The judgment includes potential royalties, but Guardant's current products are excluded. The company remains confident in its position and has validated design improvements to mitigate financial impacts.
Read more →GHTwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest
TwinStrand Biosciences announced a favorable final judgment from the U.S. District Court in a patent infringement case against Guardant Health. The court awarded TwinStrand and the University of Washington over $245.2 million in damages, royalties, and interest. This ruling upholds a previous jury verdict that found Guardant Health willfully infringed on TwinStrand's patents.
Read more →GHGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health has announced the approval of restricted stock units (RSUs) for 149 new non-executive employees. The RSUs, totaling 46,044 shares, are part of the company's 2023 Employment Inducement Incentive Award Plan. This initiative reflects Guardant's strategy to attract and retain talent as it continues to grow in the precision oncology sector.
Read more →GH▲ +6.3%on this news
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. reported its financial results for the second quarter of 2026, showing a significant increase in total revenue of 44% year-over-year. The oncology segment contributed $219.1 million, marking a 38% rise. Additionally, the company performed approximately 104,000 oncology tests, a 63% increase from the prior year.
Read more →GH▲ +5.7%on this newsshared move
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, a leader in precision oncology, has announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12 and the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 15. These events provide a platform for the company to engage with investors and discuss its innovations.
Read more →GHActor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
Guardant Health has launched a tribute video featuring Patrick Dempsey to honor over 55,000 Americans who will die from colorectal cancer this year. The video emphasizes the critical need for timely colorectal cancer screenings, as many victims are not up to date with their screenings. This initiative aims to raise awareness and encourage preventive measures.
Read more →GHGuardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
Guardant Health, a precision oncology company, will report its second quarter 2026 financial results on July 30, 2026. The announcement includes a conference call scheduled for 1:30 p.m. PT, which will be webcasted for investor access. This event highlights the company's commitment to transparency and investor relations.
Read more →GHUnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening
UnitedHealth Group has announced that it will now cover Guardant Health's Shield Blood Test for colorectal cancer screening. This test provides a non-invasive method for detecting colorectal cancer, which could lead to earlier diagnosis and treatment. The coverage expansion is expected to enhance access to this innovative screening option for patients.
Read more →About Guardant Health, Inc.
Headquarters3100 HANOVER STREET, PALO ALTO, CA, 94304
BIOPHARMAWATCH ELITE PLUS
Trade the next GH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime